

Nr. crt.	Cod protocol	Numar EudraCT	Medicament de investigatie clinica testat	Aria terapeutică	Sponsor	International / national	Denumirea studiului (s-a pastrat denumirea originala - in limba engleza)	Faza	Nr. estimat de pacienti pentru Romania	Data autorizarii studiului clinic de catre ANMDM	Data opiniei CNBMDM	Data inceperii studiului	Inchidere studiu la nivel global/ Romania
1	AB06002 Respins	2009-017930-35	Masitinib AB1010	Hemato-oncologie	AB Science	multicentric	A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethazone to placebo in combination with bortezomib and dexamethazone in the treatment of patients with relapsing multiple myeloma who received one previous therapy	III	15	11/29/2019			
2	20140346	2017-002992-25	Nplate (Romiplostim)	Oncologie	Amgen Inc., SUA	multicentric	RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Gastrointestinal or Colorectal Cancer	III	13	11/29/2019			
3	Ponatinib-3001	2018-000397-30	Ponatinib	Oncologie	Millenium Pharmaceuticals Inc., SUA	multicentric	A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)	III	14	11/29/2019	7/11/2019		
4	Vedolizumab-3035	2018-002141-11	Vedolizumab	Allogeneic Hematopoietic Stem Cell Transplantation	Millennium Pharmaceuticals Inc., SUA	multicentric	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	III	5	11/29/2019	5/16/2019		
5	ID-064A202	2018-001808-11	Cenerimod	Colagenoze	Idorsia Pharmaceuticals Ltd., Elveția	multicentric	A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE)	II	40	11/29/2019	3/21/2019		
6	CT 4006 Respins	2018-000377-68	EndoTAG-1	Oncologie	SynCore Biotechnology Co. Ltd., Taiwan	multicentric	A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment	III	19	11/29/2019	7/26/2018		
7	V130_14	2018-001857-29	Cell-derived Quadrivalent Seasonal Influenza Vaccine (QIVc)	Vaccin virus gripal	Seqirus Ltd., UK	multicentric	A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine when Administrated in Healthy Subjects aged 6 Months through 47 Months	III	385	11/29/2019	5/16/2019		
8	M14-239	2018-001772-38	Telisotuzumab Vedotin (ABBV-399)	Oncologie	AbbVie, Germania	multicentric	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer	II	6	11/29/2019	7/25/2019		

9	BGB-A317-306	2018-000587-28	Tislelizumab (BGB-A317)	Oncologie	BeiGene Ltd., SUA	multicentric	A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma	III	9	11/29/2019	4/4/2019		
10	XL184-312	2018-003354-24	Cabozantinib (XL184)	Oncologie	Exelixis Inc., SUA	multicentric	A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy	III	12	11/29/2019	6/6/2019		
11	XL184-311	2018-001771-21	Cabozantinib (XL184)	Oncologie	Exelixis Inc., SUA	multicentric	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy	III	10	11/29/2019	6/6/2019		
12	BAY 86-5321/20090	2018-002611-99	Aflibercept	Oftalmologie	Bayer AG, Germania	multicentric	Open-label, randomized, two-arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity (ROP)	III	5	11/29/2019	9/26/2019		
13	BAY 86-5321/20275	2018-003180-54	Aflibercept	Oftalmologie	Bayer AG, Germania	multicentric	An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090	III	4	11/29/2019	10/22/2019		
14	FM-17-B01	2017-000981-31	Atezolizumab	Oncologie	Fondazione Michelangelo Onlus, Italia	multicentric	Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)	III	25	11/29/2019	5/8/2019		